Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Summary

An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.

Timeline

Start

2021-09-01

Primary completion

2022-09-21

Completion

2022-09-21

Outcome

Outcome not reported

Stopped: “Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo”

Drugs

Indications